Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joao M Santos

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
IEEE Transactions on Image Processing : a Publication of the IEEE Signal Processing Society|January 31, 2022
Lossless Coding of Light Fields Based on 4D Minimum Rate PredictorsJoao M Santos, Lucas A Thomaz, Pedro A Amado Assuncao, et al.
Frontiers in Immunology|June 4, 2021
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor ControlDafne C A Quixabeira, Sadia Zafar, Joao M Santos, et al.
Oncoimmunology|January 27, 2022
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1Dafne C A Quixabeira, Victor Cervera-Carrascon, Joao M Santos, et al.
Frontiers in Immunology|July 21, 2023
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippageSanteri Pakola, Dafne C A Quixabeira, Tatiana V Kudling, et al.
Molecular Therapy Oncolytics|January 26, 2023
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumorsSaru Basnet, Joao M Santos, Dafne C A Quixabeira, et al.
Frontiers in Immunology|August 9, 2021
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1Victor Cervera-Carrascon, Dafne C A Quixabeira, Joao M Santos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 19, 2024
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokineSaru Basnet, Mirte Van der Heijden, Dafne C A Quixabeira, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 24, 2024
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokineSaru Basnet, Mirte Van der Heijden, Dafne C A Quixabeira, et al.
Molecular Therapy Oncolytics|April 24, 2020
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid TumorsVictor Cervera-Carrascon, Dafne C A Quixabeira, Riikka Havunen, et al.
Journal for Immunotherapy of Cancer|January 27, 2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trialSanteri A Pakola, James H A Clubb, Tatiana V Kudling, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
IEEE Transactions on Image Processing : a Publication of the IEEE Signal Processing Society|January 31, 2022
Lossless Coding of Light Fields Based on 4D Minimum Rate PredictorsJoao M Santos, Lucas A Thomaz, Pedro A Amado Assuncao, et al.
Frontiers in Immunology|June 4, 2021
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor ControlDafne C A Quixabeira, Sadia Zafar, Joao M Santos, et al.
Oncoimmunology|January 27, 2022
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1Dafne C A Quixabeira, Victor Cervera-Carrascon, Joao M Santos, et al.
Frontiers in Immunology|July 21, 2023
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippageSanteri Pakola, Dafne C A Quixabeira, Tatiana V Kudling, et al.
Molecular Therapy Oncolytics|January 26, 2023
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumorsSaru Basnet, Joao M Santos, Dafne C A Quixabeira, et al.
Frontiers in Immunology|August 9, 2021
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1Victor Cervera-Carrascon, Dafne C A Quixabeira, Joao M Santos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 19, 2024
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokineSaru Basnet, Mirte Van der Heijden, Dafne C A Quixabeira, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 24, 2024
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokineSaru Basnet, Mirte Van der Heijden, Dafne C A Quixabeira, et al.
Molecular Therapy Oncolytics|April 24, 2020
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid TumorsVictor Cervera-Carrascon, Dafne C A Quixabeira, Riikka Havunen, et al.
Journal for Immunotherapy of Cancer|January 27, 2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trialSanteri A Pakola, James H A Clubb, Tatiana V Kudling, et al.
Pageof 2